Hapten Immunetherapy for Liver Cancer HBV<sup>+</sup> 40 Years and Restores Normal HBV<sup>-</sup>

Chronic hepatitis B virus (HBV) infection has considered a major risk factor for the development and progression of hepatocellular carcinoma (HCC), long-term lack of effective treatment worldwide. Hapten enhanced intratumoral chemotherap may provide a revival effect of immune system to against cancer cell of HCC and HBV. Methods. Single-cell RNA sequencing (scRNA-seq) was used to analyze the changes at the molecular level of tumor reflection from the untreated tumor after HEIC treated a few multi-focal HCC tumors. Results. After treatment with major tumors, both BMEM and Naive B cells, significantly increased MHC II signaling pathway-related genes, while plasma cells upregulated MHC I-related genes. Fibroblast, γδT/NK cells and Neutrophils, while NKT cells, Plasma cells, Endothelial cells, and B cells and M2 Macrophage showed values of AUC less than 0.6 which indicated minor affection or possible minor contribution to the therapeutic effect. It was observed significantly reduced scores of HBV-infection pathways, the percentages of CSTA+DCs and Kupffer cells were reduced, showing accordance with the attenuated HBV caused inflammation. Patient of HCC HBV DNA titter drop to zero and got control of the multifocal masses of HCC who still live. It is first discovered hapten is modifiing neo HBsAg (HBsAg) while it is modifying the TAAs’s epitope, which return to a <i>neo</i> HBsAg, <i>neu</i> TAAs and rejuvenate a revival effects of immune system against cancer and HBV, i.e., by activating efficacy of CD4 T-cell activation and CD8 T-cell responses, thus, prolonging the survival time of patients, and maintaining the quality of life. Conclusions. This study provides new biological knowledge of therapy, hapten based intratumoral chemoimmunotherapy is playing an important role to improve<i> neu</i> TAAs and <i>neo</i> HBsAg for a revival of immune effect to control cancer cell and HBV in HCC with HBV positive.